NCT06100081Active, not recruitingPhase 2
Targeted fluorescence endoscopy for detection of the primary cancer lesion in patients with a metastasis of unknown primary tumor in the head and neck
REFLECT; Real-time targeted fluorescence endoscopy for detection of the primary cancer lesion in patients with a metastasis of unknown primary tumor in the head and neck
Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 Nov 2024
Brief summary (registry, in English)
To study the feasibility of identifying primary tumors in the upper aerodigestive tract in patients with unknown primary cancer with the use of targeted fluorescence endoscopy with cetuximab-800CW as the fluorescent tracer
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 8 Oct 2024
- Start date
- 8 Nov 2024
- Lead sponsor
- Universitair Medisch Centrum Groningen
- Diseases
- Head and neck cancer
- NCT number
- NCT06100081
- EU CT number
- 2024-513897-23-00
- EudraCT number
- 2018-001885-41
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 35
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent uncontrolled medical conditions
- Received an investigational drug within 30 days prior to the dose of cetuximab-800CW
- Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
Other illness
- Medical or psychiatric conditions that compromise the patient’s ability to give informed consent
- Inadequately controlled hypertension with or without current antihypertensive medications
- History of allergy or infusion reactions cetuximab or other monoclonal antibody therapies
Lab values
- History of myocardial infarction, cerebrovascular accident, uncontrolled cardiac heart failure, significant liver disease (ALT >3X upper limits of normal or increased total bilirubin) or unstable angina within 6 months prior to enrollment
- Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females)
Other
- Life expectancy < 12 weeks
- Karnofsky performance status < 70%
- Pregnant or lactating women. Documentation of a negative pregnancy test must be available for women of childbearing potential. Moreover, the need to be willing to ensure that she or her partner uses effective contraception during the trial and for 6 months thereafter. Woman of childbearing potential are premenopausal women with intact reproductive organs and women less than two years after menopause
Who the study is looking for
- Cytology and/or histology-confirmed diagnosis of squamous cell carcinoma most likely originating from the head & neck area and scheduled to undergo endoscopy of the upper aerodigestive tract as decided by the multidisciplinary head and neck tumor board of the UMCG
- The primary tumor was not identified during standard diagnostic work-up in the outpatient clinic including physical head and neck examination, fiberoptic laryngoscopy, chest X-ray, CT and PET/CT
- Age ≥ 18 years
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Medisch Centrum Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.